Vanguard Capital Management
PDSB icon

Vanguard Capital Management’s PDS Biotechnology PDSB Stock Holding History

Vanguard Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.5M Buy
1,699,315
+68,226
+4% +$72.4K ﹤0.01% 3501
2026
Q1 		$987K Buy
+1,631,089
New +$1.23M ﹤0.01% 3558

Other funds holding PDSB

Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $97.6B AUM 29.43% 1-Year Est. Return
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
MCM
Militia Capital Management Austin, Texas $3.37B AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Vanguard Capital Management's PDSB Position: Q2 2026 in Review

Vanguard Capital Management increased its PDS Biotechnology (PDSB) stake by 4.2% in Q2 2026, buying an estimated $72.4K and bringing the position to 1,699,315 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3501.

Vanguard Capital Management first reported a position in PDSB in Q1 2026 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold PDSB as of Q2 2026.

  • Vanguard Capital Management held 1,699,315 shares of PDS Biotechnology worth $1.5M as of Q2 2026.
  • Vanguard Capital Management bought 68,226 PDS Biotechnology shares in Q2 2026, an estimated $72.4K.
  • PDS Biotechnology made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3501 holding.
  • Vanguard Capital Management first reported a position in PDS Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.